Orthofix Medical Stock Forecast for 2023 - 2025 - 2030
Updated on 04/30/2024
Orthofix Medical Stock Forecast and Price Target
If Orthofix Medical's stock price reached the average yearlong target of $15.00 given by two well-known analysts in recent months, there would be a potential upside of approximately 14.59% from its last closing price in April, 2024. This potential increase is based on a high estimate of $26.40 and a low estimate of $14.00. If you're looking to buy Orthofix Medical stock, you may also want to check out its rivals.
14.59% Upside
Orthofix Medical Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Orthofix Medical's Price has decreased from $10.75 to $0.00 – a 100.00% drop. In the next year, analysts predict that Fair Value will reach $14.07 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$338.87 | Buy/Sell | $353.16 | 8.15% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$80.86 | Buy/Sell | $92.47 | 18.11% |
| BCE Stock Forecast | BCE | Hold |
10
|
C$44.73 | Buy/Sell | C$57.69 | 17.37% |
| ZBH Stock Forecast | Zimmer Biomet Holdings | Hold |
15
|
$121.71 | Buy/Sell | $132.52 | 11.74% |
Orthofix Medical Revenue Forecast for 2023 - 2025 - 2030
Orthofix Medical's Revenue has grown in the last three years, jumping from $406.56M to $746.64M – an increase of 83.65%. In the next year, analysts predict that Revenue will reach $809.09M – an increase of 8.36%. For the next nine years, the forecast is for Revenue to grow by 25.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.84 | Buy/Sell | £16.09 | 66.77% |
| GMED Stock Forecast | Globus Medical | Outperform |
16
|
$50.61 | Buy/Sell | $64.58 | 18.55% |
| ENOV Stock Forecast | Enovis | Buy |
15
|
$55.90 | Buy/Sell | $70.50 | 34.17% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMED Stock Forecast | Amedisys | Hold |
16
|
$91.84 | Buy/Sell | $97.00 | 9.97% |
| IART Stock Forecast | Integra LifeSciences Holdings | Hold |
16
|
$29.24 | Buy/Sell | $46.60 | 48.77% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$46.67 | Buy/Sell | $42.58 | 17.85% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATEC Stock Forecast | Alphatec Holdings | Buy |
7
|
$12.59 | Buy/Sell | $21.85 | 82.68% |
| NHC Stock Forecast | National HealthCare | - |
18
|
$90.52 | Buy/Sell | $47.00 | -100.00% |
| MED Stock Forecast | Medartis Holding | Outperform |
11
|
CHF81.00 | Buy/Sell | CHF101.77 | 23.77% |
Orthofix Medical EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Orthofix Medical has seen a decline in its EBITDA, from $21.11M to $-86.05M – a 507.63% decrease. According to the 3 analysts polled, in the next year, Orthofix Medical's EBITDA will fall by 181.50%, reaching $70.13M. By 2030, professionals believe that Orthofix Medical's EBITDA will have decreased by 217.02%, falling to $100.69M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDXG Stock Forecast | MiMedx Group | Buy |
6
|
$6.26 | Buy/Sell | $11.85 | 91.69% |
| KIDS Stock Forecast | OrthoPediatrics | Outperform |
7
|
$29.23 | Buy/Sell | $41.17 | 31.71% |
| ORGO Stock Forecast | Organogenesis Holdings | Outperform |
10
|
$2.46 | Buy/Sell | $4.75 | 103.25% |
Orthofix Medical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Orthofix Medical's EBIT has grown, increasing from $-13.17M to $-139.11M – a growth of 956.26%. For the next year, 3 analysts project Orthofix Medical's EBIT to drop by 51.31%, reaching $-67.73M. By 2030, professionals believe that Orthofix Medical's EBIT will decrease by 59.85%, reaching $-55.85M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AXGN Stock Forecast | AxoGen | Buy |
6
|
$6.66 | Buy/Sell | $12.50 | 110.21% |
| ANIK Stock Forecast | Anika Therapeutics | Outperform |
10
|
$25.97 | Buy/Sell | $27.33 | 23.22% |
| MODV Stock Forecast | ModivCare | Outperform |
15
|
$23.84 | Buy/Sell | $76.67 | 80.37% |
Orthofix Medical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Orthofix Medical's EPS has decreased from $0.26 to $0.00 – a 100.00% drop. In the next year, analysts predict that EPS will reach $-0.30 – an increase of 100.00%. For the next nine years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LCTX Stock Forecast | Lineage Cell Therapeutics | Outperform |
11
|
$1.12 | Buy/Sell | $5.40 | 346.43% |
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.09 | Buy/Sell | $0.69 | 0.92% |
| CGEN Stock Forecast | Compugen | Buy |
7
|
$1.98 | Buy/Sell | $4.00 | 152.53% |
.jpg)